Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros










Intervalo de ano de publicação
1.
Arch. Soc. Esp. Oftalmol ; 93(12): 617-620, dic. 2018. ilus
Artigo em Espanhol | IBECS | ID: ibc-175158

RESUMO

OBJETIVO/MÉTODOS: Describir el uso de toxina botulínica tipo A para aumentar la retención lagrimal en pacientes con ojo seco mediante el reporte de 2 casos. RESULTADOS: Pacientes con ojo seco moderado a severo, a quienes se les inyectaron 5 UI de toxina botulínica tipo A en el músculo de Horner. Se describen los resultados al mes y 3 meses. Se evaluó la percepción subjetiva del paciente en cuanto a la mejoría, además, del Ocular Surface Disease Index, la queratitis punteada superficial, el tiempo de rotura de la lágrima y el menisco lagrimal, los cuales también fueron tenidos en cuenta. Se evidenció una importante mejoría de la percepción subjetiva del paciente, el Ocular Surface Disease Index, la queratitis punteada superficial, el tiempo de rotura de la lágrima y el menisco lagrimal al mes de la aplicación, manteniéndose aún con buenos resultados al tercer mes. No se presentaron eventos adversos. DISCUSIÓN: El uso de toxina botulínica tipo A puede ser considerado una alternativa para aumentar la retención de la lágrima en pacientes con ojo seco moderado a severo con una buena respuesta durante el primer mes, manteniendo una respuesta aceptable incluso al tercer mes. Dado el efecto temporal del medicamento, podría precisar retratamientos


OBJECTIVE/METHODS: The aim of this study is to describe the use of botulinum toxin to increase tear retention in patients with dry eye, using the description of 2 cases. RESULTS: Patients with moderate to severe dry eye that were given an injection of type A botulinum toxin in the Horner's muscle. The results at one month and 3 months are reported. An assessment was made of the subjective perception of the patient as regards any improvement, as well as taking into account, the Ocular Surface Disease Index, superficial punctate keratitis, and the time of the tear rupture and tear meniscus. A significant improvement was observed in the subjective perception of the patient, the Ocular Surface Disease Index, superficial punctate keratitis, and the time of the tear rupture and tear meniscus at one month after treatment, and the good results still being maintained at the third month. There were no adverse events. DISCUSSION: The use of type A botulinum toxin can be considered as an alternative to increase tear retention in moderate to severe dry eye, with a good response during the first month, with an acceptable response still being maintained at the third month. Given the temporary effect of the drug, further treatments would be required


Assuntos
Humanos , Feminino , Pessoa de Meia-Idade , Idoso , Xeroftalmia/diagnóstico , Xeroftalmia/tratamento farmacológico , Toxinas Botulínicas Tipo A/uso terapêutico , Síndrome de Horner/diagnóstico , Síndrome de Horner/tratamento farmacológico , Ceratoconjuntivite Seca/tratamento farmacológico , Síndrome de Horner/complicações
2.
Arch Soc Esp Oftalmol (Engl Ed) ; 93(12): 617-620, 2018 Dec.
Artigo em Inglês, Espanhol | MEDLINE | ID: mdl-30001848

RESUMO

OBJECTIVE/METHODS: The aim of this study is to describe the use of botulinum toxin to increase tear retention in patients with dry eye, using the description of 2 cases. RESULTS: Patients with moderate to severe dry eye that were given an injection of type A botulinum toxin in the Horner's muscle. The results at one month and 3 months are reported. An assessment was made of the subjective perception of the patient as regards any improvement, as well as taking into account, the Ocular Surface Disease Index, superficial punctate keratitis, and the time of the tear rupture and tear meniscus. A significant improvement was observed in the subjective perception of the patient, the Ocular Surface Disease Index, superficial punctate keratitis, and the time of the tear rupture and tear meniscus at one month after treatment, and the good results still being maintained at the third month. There were no adverse events. DISCUSSION: The use of type A botulinum toxin can be considered as an alternative to increase tear retention in moderate to severe dry eye, with a good response during the first month, with an acceptable response still being maintained at the third month. Given the temporary effect of the drug, further treatments would be required.


Assuntos
Toxinas Botulínicas Tipo A/administração & dosagem , Síndromes do Olho Seco/tratamento farmacológico , Fármacos Neuromusculares/administração & dosagem , Idoso , Toxinas Botulínicas Tipo A/uso terapêutico , Pálpebras , Feminino , Humanos , Injeções Intramusculares , Lubrificantes Oftálmicos/uso terapêutico , Pessoa de Meia-Idade , Músculo Esquelético , Fármacos Neuromusculares/uso terapêutico
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...